There are no published human clinical trials evaluating Harungana madagascariensis for any indication, including its primary traditional uses of treating hemorrhoids (piles) and trypanosomiasis. All mechanistic data derive from in vitro assays on bacterial cultures, macrophage cell lines, skin cell cultures, and isolated tracheal smooth muscle tissue, which, while generating quantified IC₅₀ and MIC values, cannot be extrapolated to human effective doses or therapeutic outcomes. Pharmacological properties including antisickling and antiproliferative activities have been noted in ethnopharmacological literature but have not been subjected to controlled preclinical animal studies with reported effect sizes. Confidence in clinical efficacy for any condition is therefore very low, and use beyond traditional folk medicine contexts lacks an evidence base.
Origin
Harungana madagascariensis is a fast-growing shrub or small tree native to tropical and subtropical Africa, including Madagascar, West Africa, Central Africa, and East Africa, thriving in forest margins, disturbed habitats, and secondary vegetation at low to mid elevations. It grows prolifically in humid tropical conditions and is commonly found from Senegal to Ethiopia and southward to South Africa. The plant is not formally cultivated commercially but is harvested from wild populations for traditional medicinal use across its native range.
Potential benefits
- Antimicrobial Activity: Leaf ethanol extract (HMLE) disrupts cytoplasmic membrane integrity and inhibits catalase in Pseudomonas aeruginosa, potentiating doxycycline and tetracycline activity by at least 16-fold at subinhibitory concentrations (MIC/8).
- Anti-Inflammatory Effects: The hexane leaf fraction inhibits 15-lipoxygenase (IC₅₀ 46.80 μg/mL) and suppresses nitric oxide production (IC₅₀ 66.55 μg/mL) in LPS-stimulated macrophages, suggesting potential utility in inflammatory conditions.
- Tracheorelaxant Properties: Aqueous stem bark extract (HMAE) relaxes tracheal smooth muscle by blocking voltage-dependent and receptor-operated calcium channels, stimulating NOS-mediated nitric oxide production, antagonizing H1-histaminic receptors, and opening K⁺-ATP channels, supporting traditional use in respiratory complaints.
- Antioxidant Capacity: High concentrations of phenols and flavonoids in ethanolic leaf extracts confer significant free-radical scavenging capacity, with HMLE phenolic content among the highest reported for African medicinal plant leaf extracts.
- Skin Photoprotection and Anti-Aging: The hexane fraction reverts UVB-induced dysregulation of MMP-1, TYR, TRP-1, and COL1A1 gene expression in skin cells, suggesting protective roles against UV-mediated matrix degradation and hyperpigmentation.
- Antiprotozoal Potential: Ethnopharmacological records document use against trypanosomiasis, and phytochemical constituents including anthraquinones and triterpenoids are associated with antiprotozoal mechanisms, though in vitro confirmation remains limited.
- Alpha-Glucosidase Inhibition: A prenylated 1,4-anthraquinone isolated from the plant demonstrates alpha-glucosidase inhibitory activity, pointing to potential relevance in glycemic modulation pending further study.
How it works
HMLE exerts antibacterial effects primarily by disrupting cytoplasmic membrane integrity and inhibiting bacterial catalase activity, causing measurable hydrogen peroxide accumulation (p < 0.05) in Pseudomonas aeruginosa, which synergistically lowers minimum inhibitory concentrations of doxycycline (≥16-fold), tetracycline (≥16-fold), and kanamycin (8-fold). The hexane fraction inhibits 15-lipoxygenase, a key enzyme in the arachidonic acid inflammatory cascade, and reduces LPS-stimulated macrophage nitric oxide output, while simultaneously modulating MMP-1, TYR, TRP-1, and COL1A1 gene expression in skin cells exposed to UVB radiation. Aqueous stem bark extract (HMAE) induces tracheal smooth muscle relaxation through a multi-target mechanism: blockade of voltage-dependent calcium channels and receptor-operated calcium channels, activation of endothelial nitric oxide synthase (NOS) to produce vasodilatory NO, competitive antagonism at H1-histaminic receptors, and activation of K⁺-ATP channels leading to membrane hyperpolarization. These effects are attributed collectively to the phenolic, flavonoid, terpenoid, and anthraquinone fractions, with betulinic acid and harunganin identified as structurally notable constituents contributing to cytotoxic and anti-inflammatory profiles.
What the research says
All published research on Harungana madagascariensis is limited to in vitro cell-based and isolated-tissue studies; no human randomized controlled trials or formal animal efficacy trials with statistical power calculations have been published as of the available evidence. In vitro antibacterial studies report MIC values ranging from 16 to 2048 μg/mL for HMLE against bacterial pathogens, with antibiotic potentiation data showing statistically significant reductions (p < 0.05) in catalase activity in P. aeruginosa. Anti-inflammatory studies on LPS-stimulated macrophages and UVB-irradiated skin cell lines quantify IC₅₀ values for 15-lipoxygenase inhibition (46.80 μg/mL) and NO suppression (66.55 μg/mL), while tracheorelaxant studies use isolated guinea pig or rat tracheal tissue preparations. The overall evidence base is preclinical and fragmented across multiple extract types (ethanolic, hexane, aqueous), with no pharmacokinetic, bioavailability, or dose-escalation data available, rendering translation to clinical recommendations premature.
Safety and interactions
No formal toxicological studies, adverse event reporting, or safety assessments have been conducted for Harungana madagascariensis in humans or in standardized animal models, making it impossible to define a safe dose range, maximum tolerated dose, or no-observed-adverse-effect level. The demonstrated ability of HMLE to potentiate tetracycline-class antibiotics (≥16-fold MIC reduction) and aminoglycosides such as kanamycin (8-fold) raises a clinically important concern for pharmacokinetic or pharmacodynamic interactions if co-administered with these antibiotic classes in infected patients. Anthraquinone-containing plants as a class are associated with potential laxative effects, electrolyte disturbances with chronic use, and theoretical genotoxicity at high concentrations, though these risks have not been specifically demonstrated for this species. Pregnant and lactating individuals should avoid use given the complete absence of reproductive safety data, and individuals on antibiotic therapy, anticoagulants, or antiprotozoal medications should exercise particular caution given the mechanistic interactions identified in vitro.
Suggested use
- Traditional Aqueous Decoction (Stem Bark): Bark is boiled in water and the resulting decoction is consumed orally; no standardized volume or concentration established.
- Traditional Leaf Infusion: Fresh or dried leaves are prepared as a tea-like infusion and applied topically or consumed for wound healing and antimicrobial purposes; preparation ratios unstandardized.
- Ethanolic Leaf Extract (Research Grade): Used in in vitro studies at MIC concentrations of 16–2048 μg/mL; not formulated for human supplemental use.
- Hexane Fraction (Research Grade): Demonstrates IC₅₀ of 27.55–66.55 μg/mL for anti-inflammatory endpoints in cell assays; no capsule or oral formulation available commercially.
- Standardization: No standardized extract with defined percentages of phenols, flavonoids, or anthraquinones exists in the commercial supplement market.
- Timing and Duration: No clinical data exist to support recommendations on dosing frequency, timing relative to meals, or treatment duration.
Frequently asked questions
What is alilibarrafi used for in traditional African medicine?
Alilibarrafi (Harungana madagascariensis) has been used traditionally across sub-Saharan Africa to treat hemorrhoids (piles), trypanosomiasis, skin infections, wound healing, and respiratory conditions. The stem bark is typically prepared as an aqueous decoction for antiprotozoal and gastrointestinal complaints, while leaves are used as topical poultices. These uses are documented ethnobotanically but have not been validated in human clinical trials.
What are the main bioactive compounds in Harungana madagascariensis?
The plant's primary bioactive compounds include phenols (107.41 mg GAE/g in leaf extract), flavonoids (53.67 mg QE/g), anthraquinones, alkaloids, terpenoids, tannins, saponins, xanthones, and the specific compounds harunganin and betulinic acid isolated from the hexane fraction. A prenylated 1,4-anthraquinone with alpha-glucosidase inhibitory activity has also been identified. These secondary metabolites collectively underlie its documented antimicrobial, anti-inflammatory, and tracheorelaxant effects in laboratory studies.
Is there clinical trial evidence supporting the use of alilibarrafi as a supplement?
No human clinical trials have been conducted on alilibarrafi or Harungana madagascariensis for any health condition. All available evidence comes from in vitro studies on bacterial cultures, macrophage cell lines, skin cells, and isolated animal tracheal tissue. While these preclinical studies produce quantified data such as IC₅₀ values and MIC ranges, they cannot be directly translated into human dosing recommendations or confirmed therapeutic benefits.
Can alilibarrafi interact with antibiotics or other medications?
In vitro research shows that the ethanolic leaf extract of Harungana madagascariensis can potentiate tetracycline and doxycycline activity by at least 16-fold and kanamycin by 8-fold against Pseudomonas aeruginosa, suggesting a meaningful pharmacodynamic interaction with antibiotic drug classes. This effect is mediated through disruption of bacterial membrane integrity and inhibition of catalase activity. Individuals taking tetracycline-class antibiotics or aminoglycosides should exercise caution, and no data exist on interactions with anticoagulants, antiprotozoals, or other drug classes.
What is the safe dose of Harungana madagascariensis extract for humans?
No established safe dose exists for Harungana madagascariensis in humans, as no pharmacokinetic studies, toxicological assessments, or clinical dose-escalation trials have been conducted. Research extracts are used at concentrations of 16–2048 μg/mL (antimicrobial assays) and 27.55–66.55 μg/mL IC₅₀ (anti-inflammatory assays) in laboratory settings only. Until formal safety studies are completed, no dosing recommendation can be made, and use in vulnerable populations including pregnant or breastfeeding individuals is not advisable.
How does alilibarrafi enhance the effectiveness of doxycycline and tetracycline antibiotics?
Harungana madagascariensis leaf extract (HMLE) potentiates doxycycline and tetracycline activity by at least 16-fold through a dual mechanism: it disrupts the cytoplasmic membrane integrity of bacteria like Pseudomonas aeruginosa and inhibits their catalase enzyme. This synergistic effect occurs even at subinhibitory concentrations (MIC/8), meaning smaller doses of the antibiotic become significantly more effective when combined with alilibarrafi. However, this potent interaction requires medical supervision to avoid unintended effects.
References
This article is educational and is not medical advice. Statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before use.
